Wirkungen von Liganden der “Peroxisome Proliferator-Activated Receptors” auf die Migration von Endothelzellen und die Expression der endothelialen Adhäsionsmoleküle E-Selectin, VCAM-1 und ICAM-1Friedrich Eilers1122.1232.1.14541#34452.1.2672.289102.31133.1113.2123.313492#2463.43.4.114153.4.23.4.31617183.4.419203.4.5213.5223.623490#2513.7243.7.13.7.2253.844.14.1.1254.1.226457#7214.1.3274.1.4282930462#555548#4033132457#51433597#4974.1.53435516#6874.24.2.136524#72037511#7264.2.23839627#5584.340605#63155.140415.25.2.15.2.1.1425.2.1.2434445604#383465.2.24748495.35.3.1505.3.2515.3.352653547 Abkürzungsverzeichnis8 Herstellerverzeichnis 9 LiteraturverzeichnisEidesstattliche ErklärungDanksagungLebenslauf deInhaltsverzeichnisHilfe 9 Literaturverzeichnis 1. Abedi, H. and I. Zachary. Signalling mechanisms in the regulation of vascular cell migration. Cardiovasc.Res. 30: 544-556, 1995. 2. Abedi, H. and I. Zachary. Vascular endothelial growth factor stimulates tyrosine phosphoryl a tion and recruitment to new focal adhesions of focal adhesion kinase and paxillin in end o thelial cells. J.Biol.Chem. 272: 15442-15451, 1997. 3. Ardissino, D., P. A. Merlini, R. Ariens, R. Coppola, E. Bramucci, and P. M. Mannucci. Ti s sue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet 349: 769-771, 1997. 4. Ardissino, D., P. A. Merlini, R. Arlens, R. Coppola, E. Bramucci, S. Lucreziotti, A. Repetto, R. Fetiveau, and P. M. Mannucci. Tissue factor in human cor o nary atherosclerotic plaques. Clin.Chim.Acta 291: 235-240, 2000. 5. Bard, J. M., H. J. Parra, R. Camare, G. Luc, O. Ziegler, C. Dachet, E. Bruckert, P. Douste-Blazy, P. Drouin, B. Jacotot, et al. A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe pr i mary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein co m position. Metabolism 41: 498-503, 1992. 6. Beck, L., Jr. and P. A. D'Amore.. Vascular development: cellular and molecular regulation FASEB J. 11: 365-373, 1997. 7. Bevilacqua, M. P. Endothelial-leukocyte adhesion molecules. Annu.Rev.Immunol. 11: 767-804, 1993. 8. Bevilacqua, M. P., R. M. Nelson, G. Mannori, and O. Cecconi. Endothelial-leukocyte adhesion molecules in h u man disease. Annu.Rev.Med. 45: 361-378, 1994. 9. Bishop-Bailey, D. Peroxisome proliferator-activated receptors in the cardiova s cular system. Br.J.Pharmacol. 129: 823-834, 2000. 10. Bishop-Bailey, D. and T. Hla. Endothelial cell apoptosis induced by the peroxisome proliferator- activated rece p tor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2. J.Biol.Chem. 274: 17042-17048, 1999. 11. Butcher, E. C. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 67: 1033-1036, 1991. 12. Carlos, T. M. and J. M. Harlan. Leukocyte-endothelial adhesion molecules. Blood 84: 2068-2101, 1994. 13. Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis. Nat.Med. 6: 389-395, 2000. 14. Castrillo, A., M. J. Diaz-Guerra, S. Hortelano, P. Martin-Sanz, and L. Bosca. Inhibition of IkappaB kinase and IkappaB phosphorylation by 15-deoxy- Delta(12,14)-prostaglandin J(2) in activated murine macrophages. Mol.Cell Biol. 20: 1692-1698, 2000. 15. Chen, N. G., S. F. Sarabia, P. J. Malloy, X. Y. Zhao, D. Feldman, and G. M. Reaven. PPARgamma agonists e n hance human vascular endothelial adhesiveness by increasing ICAM-1 expression. Biochem.Biophys.Res.Commun. 263: 718-722, 1999. 16. Chen, Y. X., Y. Nakashima, K. Tanaka, S. Shiraishi, K. Nakagawa, and K. Sueishi. Immunohistochemical e x pression of vascular endothelial growth factor/vascular permeability factor in atherosclerotic intimas of human coronary arteries. Arterioscler.Thromb.Vasc.Biol. 19: 131-139, 1999. 17. Cheresh, D. A., J. Leng, and R. L. Klemke. Regulation of cell contraction and membrane ruffling by distinct signals in migratory cells. J.Cell Biol. 146: 1107-1116, 1999. 18. Chinetti, G., J. C. Fruchart, and B. Staels. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors with functions in the vascular wall. Z.Kardiol. 90 Suppl 3: 125-132, 2001. 19. Chinetti, G., S. Griglio, M. Antonucci, I. P. Torra, P. Delerive, Z. Majd, J. C. Fruchart, J. Chapman, J. Najib, and B. Staels. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J.Biol.Chem. 273: 25573-25580, 1998. 20. Cho, A., J. Graves, and M. A. Reidy. Mitogen-activated protein kinases mediate matrix me t alloproteinase-9 expression in vascular smooth muscle cells. Arterioscler.Thromb.Vasc.Biol. 20: 2527-2532, 2000. 21. Cho, S. Y. and R. L. Klemke. Extracellular-regulated kinase activation and CAS/Crk coupling regulate cell m i gration and suppress apoptosis during i n vasion of the extracellular matrix. J.Cell Biol. 149: 223-236, 2000. 22. Collins, A. R., W. P. Meehan, U. Kintscher, S. Jackson, S. Wakino, G. Noh, W. Palinski, W. A. Hsueh, and R. E. Law. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler.Thromb.Vasc.Biol. 21: 365-371, 2001. 23. Collins, R. G., R. Velji, N. V. Guevara, M. J. Hicks, L. Chan, and A. L. Beaudet. P-Selectin or intercellular adh e sion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein E- def i cient mice. J.Exp.Med. 191: 189-194, 2000. 24. Collins, T., M. A. Read, A. S. Neish, M. Z. Whitley, D. Thanos, and T. Maniatis. Transcri p tional regulation of endothelial cell adhesion molecules: NF- kappa B and cytokine-inducible enhancers. FASEB J. 9: 899-909, 1995. 25. Conway, E. M., D. Collen, and P. Carmeliet. Molecular mechanisms of blood vessel growth. Cardiovasc.Res. 49: 507-521, 2001. 26. Couffinhal, T., M. Kearney, B. Witzenbichler, D. Chen, T. Murohara, D. W. Losordo, J. Symes, and J. M. Isner. Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in normal and atherosclerotic human arteries. Am.J.Pathol. 150: 1673-1685, 1997. 27. Cybulsky, M. I. and M. A. Gimbrone, Jr. Endothelial expression of a monon u clear leukocyte adhesion molecule during atherogenesis. Science 251: 788-791, 1991. 28. Davies, M. J., J. L. Gordon, A. J. Gearing, R. Pigott, N. Woolf, D. Katz, and A. Kyriakopo u los. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E- s e lectin in human atherosclerosis. J.Pathol. 171: 223-229, 1993. 29. Davignon, J. Advances in lipid-lowering therapy in atherosclerosis. Adv.Exp.Med.Biol. 498: 49-58, 2001. 30. de Boer, O. J., A. C. van der Wal, P. Teeling, and A. E. Becker. Leucocyte recruitment in rupture prone regions of lipid-rich plaques: a prominent role for neovascularization? Cardiovasc.Res. 41: 443-449, 1999. 31. Debril, M. B., J. P. Renaud, L. Fajas, and J. Auwerx. The pleiotropic functions of pero x isome proliferator-activated receptor gamma. J.Mol.Med. 79: 30-47, 2001. 32. Delerive, P., K. De Bosscher, S. Besnard, W. Vanden Berghe, J. M. Peters, F. J. Gonzalez, J. C. Fruchart, A. Te d gui, G. Haegeman, and B. Staels. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription fa c tors NF-kappaB and AP-1. J.Biol.Chem. 274: 32048-32054, 1999. 33. Delerive, P., P. Gervois, J. C. Fruchart, and B. Staels. Induction of IkappaBa l pha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activ a tors. J.Biol.Chem. 275: 36703-36707, 2000. 34. Delerive, P., F. Martin-Nizard, G. Chinetti, F. Trottein, J. C. Fruchart, J. Najib, P. Duriez, and B. Staels. Pero x isome proliferator-activated receptor activators inhibit thrombin- i n duced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ.Res. 85: 394-402, 1999. 35. Dimmeler, S., B. Assmus, C. Hermann, J. Haendeler, and A. M. Zeiher. Fluid shear stress stimulates phosphor y lation of Akt in human endothelial cells: involvement in suppression of apoptosis. Circ.Res. 83: 334-341, 1998. 36. Dimmeler, S., E. Dernbach, and A. M. Zeiher. Phosphorylation of the endoth e lial nitric oxide synthase at ser-1177 is required for VEGF-induced end o thelial cell migration. FEBS Lett. 477: 258-262, 2000. 37. Dimmeler, S., I. Fleming, B. Fisslthaler, C. Hermann, R. Busse, and A. M. Ze i her. Activation of nitric oxide synthase in endothelial cells by Akt- dependent phosphorylation. Nature 399: 601-605, 1999. 38. Dimmeler, S. and A. M. Zeiher. Akt takes center stage in angiogenesis signa l ing. Circ.Res. 86: 4-5, 2000. 39. Dong, Z. M., S. M. Chapman, A. A. Brown, P. S. Frenette, R. O. Hynes, and D. D. Wagner. The combined role of P- and E-selectins in atherosclerosis. J.Clin.Invest 102: 145-152, 1998. 40. Ericsson, C. G., A. Hamsten, J. Nilsson, L. Grip, B. Svane, and U. de Faire. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 347: 849-853, 1996. 41. Ferrara, N. and T. Davis-Smyth. The biology of vascular endothelial growth factor. Endocr.Rev. 18: 4-25, 1997. 42. Ferri, C., C. Bellini, G. Desideri, L. Di Francesco, R. Baldoncini, A. Santucci, and G. De Mattia. Plasma end o thelin-1 levels in obese hypertensive and normotensive men. Diabetes 44: 431-436, 1995. 43. Ferri, C., V. Pittoni, A. Piccoli, O. Laurenti, M. R. Cassone, C. Bellini, G. Properzi, G. Val e sini, G. De Mattia, and A. Santucci. Insulin stimulates endothelin-1 secretion from human endothelial cells and modulates its circula t ing levels in vivo. J.Clin.Endocrinol.Metab 80: 829-835, 1995. 44. Ferris, F. L., III, M. D. Davis, and L. M. Aiello. Treatment of diabetic ret i nopathy. N.Engl.J.Med. 341: 667-678, 1999. 45. Forman, B. M., J. Chen, and R. M. Evans. Hypolipidemic drugs, polyunsat u rated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc.Natl.Acad.Sci.U.S.A 94: 4312-4317, 1997. 46. Franke, R. P., M. Gräfe, H. Schnittler, D. Seiffge, C. Mittermayer, and D. Drenckhahn. Induction of human va s cular endothelial stress fibres by fluid shear stress. Nature 307: 648-649, 1984. 47. Franke, T. F., S. I. Yang, T. O. Chan, K. Datta, A. Kazlauskas, D. K. Morrison, D. R. Ka p lan, and P. N. Tsichlis. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinos i tol 3-kinase. Cell 81: 727-736, 1995. 48. Frick, M. H., M. Syvanne, M. S. Nieminen, H. Kauma, S. Majahalme, V. Virtanen, Y. A. Kesaniemi, A. Paste r nack, and M. R. Taskinen. Prevention of the angiographic progression of coronary and vein-graft ather o sclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 96: 2137-2143, 1997. 49. Fulton, D., J. P. Gratton, T. J. McCabe, J. Fontana, Y. Fujio, K. Walsh, T. F. Franke, A. P a papetropoulos, and W. C. Sessa. Regula tion of endothelium-derived nitric oxide produ c tion by the protein kinase Akt. Nature 399: 597-601, 1999. 50. Glass, C. K. and J. L. Witztum. Atherosclerosis. the road ahead. Cell 104: 503-516, 2001. 51. Goetze, S., A. Bungenstock, C. Czupalla, F. Eilers, P. Stawowy, U. Kintscher, C. Spencer-Hänsch, K. Graf, B. Nürnberg, R. E. Law, E. Fleck, and M. Gräfe. Leptin induces end o thelial cell migration through Akt, which is inhibited by PPARgamma-ligands. Hypertension 40: 748-754, 2002. 52. Goetze, S., U. Kintscher, K. Kaneshiro, W. P. Meehan, A. Collins, E. Fleck, W. A. Hsueh, and R. E. Law. TNFa l pha induces expression of transcription factors c-fos, Egr-1, and Ets-1 in vascular lesions through extrace l lular signal-regulated kinases 1/2. Atherosclerosis 159: 93-101, 2001. 53. Goetze, S., U. Kintscher, S. Kim, W. P. Meehan, K. Kaneshiro, A. R. Collins, E. Fleck, W. A. Hsueh, and R. E. Law. Peroxisome proliferator-activated receptor-gamma ligands inhibit nuclear but not cytosolic extracell u lar si g nal-regulated kinase/mitogen-activated protein kinase-regulated steps in vascular smooth muscle cell migration. J.Cardiovasc.Pharmacol. 38: 909-921, 2001. 54. Goetze, S., X. P. Xi, K. Graf, E. Fleck, W. A. Hsueh, and R. E. Law. Troglit a zone inhibits angiotensin II-induced extracellular signal- regulated kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells. FEBS Lett. 452: 277-282, 1999. 55. Goetze, S., X. P. Xi, H. Kawano, T. Gotlibowski, E. Fleck, W. A. Hsueh, and R. E. Law. PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vasc u lar smooth muscle cells. J.Cardiovasc.Pharmacol. 33: 798-806, 1999. 56. Goetze, S., X. P. Xi, Y. Kawano, H. Kawano, E. Fleck, W. A. Hsueh, and R. E. Law. TNF-alpha-induced migr a tion of vascular smooth muscle cells is MAPK dependent. Hypertension 33: 183-189, 1999. 57. Gouni-Berthold, I., H. K. Berthold, A. A. Weber, Y. Ko, C. Seul, H. Vetter, and A. Sachin i dis. Troglitazone and rosiglitazone induce apoptosis of va s cular smooth muscle cells through an extracellular signal-regulated kinase- independent pathway. Naunyn Schmiedebergs Arch.Pharmacol. 363: 215-221, 2001. 58. Gräfe, M., W. Auch-Schwelk, K. Graf, D. Terbeek, H. Hertel, M. Unkelbach, A. Hildebrandt, and E. Fleck. Is o lation and characterization of macrovascular and microvascular endothelial cells from human hearts. Am.J.Physiol 267: H2138-H2148, 1994. 59. Gräfe, M., W. Auch-Schwelk, H. Hertel, D. Terbeek, G. Steinheider, M. Lo e be, and E. Fleck. Human cardiac microvascular and macrovascular endoth e lial cells respond differently to oxidatively modified LDL. Atherosclerosis 137: 87-95, 1998. 60. Gräfe, M., W. Auch-Schwelk, A. Zakrzewicz, V. Regitz-Zagrosek, P. Bartsch, K. Graf, M. Loebe, P. Gaehtgens, and E. Fleck. Angiotensin II-induced leukocyte adhesion on human coronary endothelial cells is mediated by E-selectin. Circ.Res. 81: 804-811, 1997. 61. Gräfe, M., K. Graf, W. Auch-Schwelk, D. Terbeek, H. Hertel, and E. Fleck. Cultivation and characterization of micro- and macrovascular endothelial cells from the human heart. Eur.Heart J. 14 Suppl I: 74-81, 1993. 62. Gräfe, M., G. Steinheider, U. Desaga, C. Warnecke, H. B. Lehmkuhl, V. R e gitz-Zagrosek, A. G. Hildebrandt, and E. Fleck. Characterization of two distinct mechanisms for induction of apoptosis in human vascular end o thelial cells. Clin.Chem.Lab Med. 37: 505-510, 1999. 63. Gräfe, M., A. Zakrzewicz, K. Graf, P. Gaehtgens, and E. Fleck. [Differential reaction of h u man cardiac macro- and microvascular endothelial cells with respect to leucocyte adhesion and exposition to atherogenic lip o proteins]. Z.Kardiol. 88: 828-837, 1999. 64. Gutstein, D. E. and V. Fuster. Pathophysiology and clinical significance of atherosclerotic plaque rupture. Cardiovasc.Res. 41: 323-333, 1999. 65. Han, K. H., M. K. Chang, A. Boullier, S. R. Green, A. Li, C. K. Glass, and O. Quehenberger. Oxidized LDL reduces monocyte CCR2 expression through pathways involving pero x isome proliferator-activated receptor gamma. J.Clin.Invest 106: 793-802, 2000. 66. Harker, L. A., A. B. Kelly, S. R. Hanson, W. Krupski, A. Bass, B. Osterud, G. A. FitzGerald, S. H. Goodnight, and W. E. Connor. Interruption of vasc u lar thrombus formation and vascular lesion formation by dietary n-3 fatty acids in fish oil in nonhuman primates. Circulation 87: 1017-1029, 1993. 67. Hinton, D. R., S. He, K. Graf, D. Yang, W. A. Hsueh, S. J. Ryan, and R. E. Law. Mitogen-activated protein kinase activation mediates PDGF-directed migration of RPE cells. Exp.Cell Res. 239: 11-15, 1998. 68. Hsueh, W. A. and R. E. Law. Cardiovascular risk continuum: implications of insulin resi s tance and diabetes. Am.J.Med. 105: 4S-14S, 1998. 69. Hsueh, W. A. and R. E. Law. Diabetes is a vascular disease. J.Investig.Med. 46: 387-390, 1998. 70. Hu, R. M., E. R. Levin, A. Pedram, and H. J. Frank. Insulin stimulates production and secr e tion of endothelin from bovine endothelial cells. Diabetes 42: 351-358, 1993. 71. Inoue, I., K. Shino, S. Noji, T. Awata, and S. Katayama. Expression of peroxisome prolifer a tor-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells. Biochem.Biophys.Res.Commun. 246: 370-374, 1998. 72. Inoue, M., H. Itoh, M. Ueda, T. Naruko, A. Kojima, R. Komatsu, K. Doi, Y. Ogawa, N. T a mura, K. Takaya, T. Igaki, J. Yamashita, T. H. Chun, K. Masatsugu, A. E. Becker, and K. Nakao. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological signif i cance of VEGF in progression of atherosclerosis. Circulation 98: 2108-2116, 1998. 73. Isner, J. M. Cancer and atherosclerosis: the broad mandate of angiogenesis. Circulation 99: 1653-1655, 1999. 74. Jackson, S. M., F. Parhami, X. P. Xi, J. A. Berliner, W. A. Hsueh, R. E. Law, and L. L. Demer. Peroxisome pr o liferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell i n teraction. Arterioscler.Thromb.Vasc.Biol. 19: 2094-2104, 1999. 75. Jaffe, E. A., R. L. Nachman, C. G. Becker, and C. R. Minick. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic crit e ria. J.Clin.Invest 52: 2745-2756, 1973. 76. Jiang, C., A. T. Ting, and B. Seed. PPAR-gamma agonists inhibit production of monocyte inflammatory cyt o kines. Nature 391: 82-86, 1998. 77. Kato, K., H. Satoh, Y. Endo, D. Yamada, S. Midorikawa, W. Sato, K. Mizuno, T. Fujita, K. Tsukamoto, and T. Watanabe. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function. Biochem.Biophys.Res.Commun. 258: 431-435, 1999. 78. Keller, H., C. Dreyer, J. Medin, A. Mahfoudi, K. Ozato, and W. Wahli. Fatty acids and ret i noids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor he t erodimers. Proc.Natl.Acad.Sci.U.S.A 90: 2160-2164, 1993. 79. Kersten, S., B. Desvergne, and W. Wahli. Roles of PPARs in health and disease. Nature 405: 421-424, 2000. 80. Kintscher, U., S. Goetze, S. Wakino, S. Kim, S. Nagpal, R. A. Chandraratna, K. Graf, E. Fleck, W. A. Hsueh, and R. E. Law. Peroxisome proliferator-activated receptor and ret i noid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes. Eur.J.Pharmacol. 401: 259-270, 2000. 81. Kume, N., M. I. Cybulsky, and M. A. Gimbrone, Jr. Lysophosphatidylcholine, a component of atherogenic lip o proteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endoth e lial cells. J.Clin.Invest 90: 1138-1144, 1992. 82. Kwon, H. M., G. Sangiorgi, E. L. Ritman, C. McKenna, D. R. Holmes, Jr., R. S. Schwartz, and A. Lerman. E n hanced coronary vasa vasorum neovascularization in experimental h y percholesterolemia. J.Clin.Invest 101: 1551-1556, 1998. 83. Lamoreaux, W. J., M. E. Fitzgerald, A. Reiner, K. A. Hasty, and S. T. Charles. Vascular e n dothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by m i crovascular endothelial cells in vitro. Microvasc.Res. 55: 29-42, 1998. 84. Law, R. E., S. Goetze, X. P. Xi, S. Jackson, Y. Kawano, L. Demer, M. C. Fishbein, W. P. Meehan, and W. A. Hsueh. Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation 101: 1311-1318, 2000. 85. Law, R. E., W. P. Meehan, X. P. Xi, K. Graf, D. A. Wuthrich, W. Coats, D. Faxon, and W. A. Hsueh. Troglitazone inhibits vascular smooth muscle cell growth and intimal hype r plasia. J.Clin.Invest 98: 1897-1905, 1996. 86. Lee, H., W. Shi, P. Tontonoz, S. Wang, G. Subbanagounder, C. C. Hedrick, S. Hama, C. Borromeo, R. M. Evans, J. A. Berliner, and L. Nagy. Role for peroxisome proliferator-activated receptor alpha in oxidized phospho l ipid-induced synthesis of monocyte chem o tactic protein-1 and interleukin-8 by endothelial cells. Circ.Res. 87: 516-521, 2000. 87. Lee, P., C. C. Wang, and A. P. Adamis. Ocular neovascularization: an epidemiologic review. Surv.Ophthalmol. 43: 245-269, 1998. 88. Li, A. C., K. K. Brown, M. J. Silvestre, T. M. Willson, W. Palinski, and C. K. Glass. Pero x isome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J.Clin.Invest 106: 523-531, 2000. 89. Li, H., M. I. Cybulsky, M. A. Gimbrone, Jr., and P. Libby. An atherogenic diet rapidly induces VCAM-1, a cyt o kine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler.Thromb. 13: 197-204, 1993. 90. Li, H., M. I. Cybulsky, M. A. Gimbrone, Jr., and P. Libby. Inducible expression of vascular cell adhesion mol e cule-1 by vascular smooth muscle cells in vitro and within rabbit atheroma. Am.J.Pathol. 143: 1551-1559, 1993. 91. Lin, J. H., Y. Zhu, H. L. Liao, Y. Kobari, L. Groszek, and M. B. Stemerman. Induction of vascular cell adhesion molecule-1 by low-density lipoprotein. Atherosclerosis 127: 185-194, 1996. 92. Loskutoff, D. J. and F. Samad. The adipocyte and hemostatic balance in obesity: studies of PAI-1. Arterioscler.Thromb.Vasc.Biol. 18: 1-6, 1998. 93. Luscinskas, F. W., M. I. Cybulsky, J. M. Kiely, C. S. Peckins, V. M. Davis, and M. A. Gi m brone, Jr. Cytokine-activated human endothelial monolayers support enhanced neutrophil transmigration via a mechanism i n volving both endothelial- leukocyte adhesion mol e cule-1 and intercellular adhesion molecule-1. J.Immunol. 146: 1617-1625, 1991. 94. Lusis, A. J. Atherosclerosis. Nature 407: 233-241, 2000. 95. Mackay, C. R. Chemokine receptors and T cell chemotaxis. J.Exp.Med. 184: 799-802, 1996. 96. Maggs, D. G., T. A. Buchanan, C. F. Burant, G. Cline, B. Gumbiner, W. A. Hsueh, S. Inzu c chi, D. Kelley, J. Nolan, J. M. Olefsky, K. S. Polonsky, D. Silver, T. R. Valiquett, and G. I. Shulman. Metabolic effects of tr o glitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann.Intern.Med. 128: 176-185, 1998. 97. Marx, N., T. Bourcier, G. K. Sukhova, P. Libby, and J. Plutzky. PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler.Thromb.Vasc.Biol. 19: 546-551, 1999. 98. Marx, N., J. Froehlich, L. Siam, J. Ittner, G. Wierse, A. Schmidt, H. Scharnagl, V. Hombach, and W. Koenig. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 s e rum levels in type 2 diabetic patients with coronary artery disease. Arterioscler.Thromb.Vasc.Biol. 23: 283-288, 2003. 99. Marx, N., A. Imhof, J. Froehlich, L. Siam, J. Ittner, G. Wierse, A. Schmidt, W. Maerz, V. Hombach, and W. Koenig. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 107: 1954-1957, 2003. 100. Marx, N., F. Mach, A. Sauty, J. H. Leung, M. N. Sarafi, R. M. Ransohoff, P. Libby, J. Plutzky, and A. D. Luster. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN- gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J.Immunol. 164: 6503-6508, 2000. 101. Marx, N., N. Mackman, U. Schonbeck, N. Yilmaz, V. Hombach, V, P. Libby, and J. Plutzky. PPARalpha Activ a tors Inhibit Tissue Factor Expression and Activity in Human Monocytes. Circulation 103: 213-219, 2001. 102. Marx, N., U. Schonbeck, M. A. Lazar, P. Libby, and J. Plutzky. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human va s cular smooth muscle cells. Circ.Res. 83: 1097-1103, 1998. 103. Marx, N., G. Sukhova, C. Murphy, P. Libby, and J. Plutzky. Macrophages in human atheroma contain PPARgamma: differentiation- dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am.J.Pathol. 153: 17-23, 1998. 104. Marx, N., G. K. Sukhova, T. Collins, P. Libby, and J. Plutzky. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99: 3125-3131, 1999. 105. Meili, R., C. Ellsworth, S. Lee, T. B. Reddy, H. Ma, and R. A. Firtel. Chemoattractant-mediated transient act i vation and membrane localization of Akt/PKB is required for efficient chemotaxis to cAMP in Dictyo s telium. EMBO J. 18: 2092-2105, 1999. 106. Morales-Ruiz, M., D. Fulton, G. Sowa, L. R. Languino, Y. Fujio, K. Walsh, and W. C. Sessa. Vascular endoth e lial growth factor-stimulated actin reorganization and migration of endothelial cells is regulated via the se r ine/threonine kinase Akt. Circ.Res. 86: 892-896, 2000. 107. Moulton, K. S., E. Heller, M. A. Konerding, E. Flynn, W. Palinski, and J. Folkman. Angi o genesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 99: 1726-1732, 1999. 108. Murao, K., H. Imachi, A. Momoi, Y. Sayo, H. Hosokawa, M. Sato, T. Ishida, and J. Takahara. Thiazolidi n edione inhibits the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells. FEBS Lett. 454: 27-30, 1999. 109. Murata, T., Y. Hata, T. Ishibashi, S. Kim, W. A. Hsueh, R. E. Law, and D. R. Hinton. R e sponse of experimental retinal neovascularization to thiazolidinediones. Arch.Ophthalmol. 119: 709-717, 2001. 110. Murata, T., S. He, M. Hangai, T. Ishibashi, X. P. Xi, S. Kim, W. A. Hsueh, S. J. Ryan, R. E. Law, and D. R. Hinton. Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization. Invest Ophthalmol.Vis.Sci. 41: 2309-2317, 2000. 111. Neve, B. P., J. C. Fruchart, and B. Staels. Role of the peroxisome proliferator-activated r e ceptors (PPAR) in atherosclerosis. Biochem.Pharmacol. 60: 1245-1250, 2000. 112. Nilsson, L., T. Takemura, P. Eriksson, and A. Hamsten. Effects of fibrate compounds on expression of plasm i nogen activator inhibitor-1 by cultured endothelial cells. Arterioscler.Thromb.Vasc.Biol. 19: 1577-1581, 1999. 113. O'Brien, E. R., M. R. Garvin, R. Dev, D. K. Stewart, T. Hinohara, J. B. Simpson, and S. M. Schwartz. Angi o genesis in human coronary atherosclerotic plaques. Am.J.Pathol. 145: 883-894, 1994. 114. O'Brien, K. D., T. O. McDonald, A. Chait, M. D. Allen, and C. E. Alpers. Neovascular e x pression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation 93: 672-682, 1996. 115. Oda, N., M. Abe, and Y. Sato. ETS-1 converts endothelial cells to the angiogenic phenotype by inducing the expression of matrix metalloproteinases and integrin beta3. J.Cell Physiol 178: 121-132, 1999. 116. Okura, T., M. Nakamura, Y. Takata, S. Watanabe, Y. Kitami, and K. Hiwada. Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells. Eur.J.Pharmacol. 407: 227-235, 2000. 117. Olefsky, J. M. Treatment of insulin resistance with peroxisome proliferator-activated rece p tor gamma agonists. J.Clin.Invest 106: 467-472, 2000. 118. Papapetropoulos, A., G. Garcia-Cardena, J. A. Madri, and W. C. Sessa. Nitric oxide produ c tion contributes to the angiogenic properties of vascular endothelial growth factor in h u man endothelial cells. J.Clin.Invest 100: 3131-3139, 1997. 119. Pasceri, V., H. D. Wu, J. T. Willerson, and E. T. Yeh. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 101: 235-238, 2000. 120. Pauly, R. R., A. Passaniti, C. Bilato, R. Monticone, L. Cheng, N. Papadopoulos, Y. A. Gluzband, L. Smith, C. Weinstein, E. G. Lakatta, and . Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. Circ.Res. 75: 41-54, 1994. 121. Pedram, A., M. Razandi, and E. R. Levin. Extracellular signal-regulated protein kinase/Jun kinase cross-talk underlies vascular endothelial cell growth factor-induced endothelial cell proliferation. J.Biol.Chem. 273: 26722-26728, 1998. 122. Petrova, T. V., K. T. Akama, and L. J. Van Eldik. Cyclopentenone prostaglandins suppress activation of micr o glia: down- regulation of inducible nitric-oxide synthase by 15-deoxy-Delta12,14- prostaglandin J2. Proc.Natl.Acad.Sci.U.S.A 96: 4668-4673, 1999. 123. Petruzzelli, L., M. Takami, and H. D. Humes. Structure and function of cell adhesion mol e cules. Am.J.Med. 106: 467-476, 1999. 124. Plutzky, J. Atherosclerotic plaque rupture: emerging insights and opportunities. Am.J.Cardiol. 84: 15J-20J, 1999. 125. Pober, J. S. and R. S. Cotran. The role of endothelial cells in inflammation. Transplantation 50: 537-544, 1990. 126. Poston, R. N., D. O. Haskard, J. R. Coucher, N. P. Gall, and R. R. Johnson-Tidey. Expre s sion of intercellular adhesion molecule-1 in atherosclerotic plaques. Am.J.Pathol. 140: 665-673, 1992. 127. Ramos, M. A., M. Kuzuya, T. Esaki, S. Miura, S. Satake, T. Asai, S. Kanda, T. Hayashi, and A. Iguchi. Indu c tion of macrophage VEGF in response to oxidized LDL and VEGF accumulation in human atherosclerotic lesions. Arterioscler.Thromb.Vasc.Biol. 18: 1188-1196, 1998. 128. Ricote, M., A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass. The peroxisome proliferator-activated rece p tor-gamma is a negative regulator of macrophage activation. Nature 391: 79-82, 1998. 129. Rosen, E. D. and B. M. Spiegelman. Peroxisome proliferator-activated receptor gamma ligands and atheroscl e rosis: ending the heartache. J.Clin.Invest 106: 629-631, 2000. 130. Ross, R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362: 801-809, 1993. 131. Ross, R. Atherosclerosis--an inflammatory disease. N.Engl.J.Med. 340: 115-126, 1999. 132. Rossi, A., P. Kapahi, G. Natoli, T. Takahashi, Y. Chen, M. Karin, and M. G. Santoro. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 403: 103-108, 2000. 133. Rubins, H. B., S. J. Robins, D. Collins, C. L. Fye, J. W. Anderson, M. B. Elam, F. H. Faas, E. Linares, E. J. Schaefer, G. Schectman, T. J. Wilt, and J. Wittes. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Interve n tion Trial Study Group. N.Engl.J.Med. 341: 410-418, 1999. 134. Saitoh, K., T. Mori, H. Kasai, T. Nagayama, and S. Ohbayashi. [Anti-atheromatous effects of fenofibrate, a hypolipidemic drug. II: Anti-atheromatous effects are independent of its hypolipidemic effect in hereditary hyperlipidemic rabbits]. Nippon Yakurigaku Zasshi 106: 51-60, 1995. 135. Saitoh, K., T. Mori, H. Kasai, T. Nagayama, A. Tsuchiya, and S. Ohbayashi. [Anti-atheromatous effects of fenofibrate, a hypolipidemic drug. I: Anti-atheromatous effects are independent of its hypolipidemic effect in cholesterol-fed rabbits]. Nippon Yakurigaku Zasshi 106: 41-50, 1995. 136. Satoh, H., K. Tsukamoto, Y. Hashimoto, N. Hashimoto, M. Togo, M. Hara, H. Maekawa, N. Isoo, S. Kimura, and T. Watanabe. Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARgamma on vascular endothelial function. Biochem.Biophys.Res.Commun. 254: 757-763, 1999. 137. Schneiderman, J., M. S. Sawdey, M. R. Keeton, G. M. Bordin, E. F. Bernstein, R. B. Dilley, and D. J. Loskutoff. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arte r ies. Proc.Natl.Acad.Sci.U.S.A 89: 6998-7002, 1992. 138. Schoonjans, K., B. Staels, and J. Auwerx. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J.Lipid Res. 37: 907-925, 1996. 139. Seger, R. and E. G. Krebs. The MAPK signaling cascade. FASEB J. 9: 726-735, 1995. 140. Shih, P. T., M. L. Brennan, D. K. Vora, M. C. Territo, D. Strahl, M. J. Elices, A. J. Lusis, and J. A. Berliner. Blocking very late antigen-4 integrin decreases leukocyte entry and fatty streak formation in mice fed an atherogenic diet. Circ.Res. 84: 345-351, 1999. 141. Shu, H., B. Wong, G. Zhou, Y. Li, J. Berger, J. W. Woods, S. D. Wright, and T. Q. Cai. Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. Biochem.Biophys.Res.Commun. 267: 345-349, 2000. 142. Slupsky, C. M., L. N. Gentile, L. W. Donaldson, C. D. Mackereth, J. J. Seidel, B. J. Graves, and L. P. McIntosh. Structure of the Ets-1 pointed domain and mitogen-activated protein kinase phosphorylation site. Proc.Natl.Acad.Sci.U.S.A 95: 12129-12134, 1998. 143. Sobel, B. E. Insulin resistance and thrombosis: a cardiologist's view. Am.J.Cardiol. 84: 37J-41J, 1999. 144. Sowers, J. R., M. Epstein, and E. D. Frohlich. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 37: 1053-1059, 2001. 145. Spencer, C. M. and A. Markham. Troglitazone. Drugs 54: 89-101, 1997. 146. Spiegelman, B. M. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47: 507-514, 1998. 147. Staels, B., J. Dallongeville, J. Auwerx, K. Schoonjans, E. Leitersdorf, and J. C. Fruchart. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98: 2088-2093, 1998. 148. Takagi, T., T. Akasaka, A. Yamamuro, Y. Honda, T. Hozumi, S. Morioka, and K. Yoshida. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent di a betes mellitus: a serial intravascular ultrasound study. J.Am.Coll.Cardiol. 36: 1529-1535, 2000. 149. Tenaglia, A. N., K. G. Peters, M. H. Sketch, Jr., and B. H. Annex. Neovascularization in atherectomy specimens from patients with unstable angina: implications for pathogenesis of unstable angina. Am.Heart J. 135: 10-14, 1998. 150. Tontonoz, P., L. Nagy, J. G. Alvarez, V. A. Thomazy, and R. M. Evans. PPARgamma promotes mon o cyte/macrophage differentiation and uptake of oxidized LDL. Cell 93: 241-252, 1998. 151. van der Wal, A. C. and A. E. Becker. Atherosclerotic plaque rupture--pathologic basis of plaque stability and instability. Cardiovasc.Res. 41: 334-344, 1999. 152. van der Wal, A. C., P. K. Das, A. J. Tigges, and A. E. Becker. Adhesion molecules on the endothelium and mononuclear cells in human atherosclerotic lesions. Am.J.Pathol. 141: 1427-1433, 1992. 153. Waltenberger, J. Impaired collateral vessel development in diabetes: potential cellular mechanisms and ther a peutic implications. Cardiovasc.Res. 49: 554-560, 2001. 154. Weil, A., J. Caldwell, and M. Strolin-Benedetti. The metabolism and disposition of 14C-fenofibrate in human volunteers. Drug Metab Dispos. 18: 115-120, 1990. 155. Wheeler-Jones, C., R. Abu-Ghazaleh, R. Cospedal, R. A. Houliston, J. Martin, and I. Zachary. Vascular end o thelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in e n dothelial cells via p42/p44 mitogen-activated protein kinase. FEBS Lett. 420: 28-32, 1997. 156. Willson, T. M., P. J. Brown, D. D. Sternbach, and B. R. Henke. The PPARs: from orphan receptors to drug discovery. J.Med.Chem. 43: 527-550, 2000. 157. Wymann, M. P. and L. Pirola. Structure and function of phosphoinositide 3-kinases. Biochim.Biophys.Acta 1436: 127-150, 1998. 158. Xi, X. P., K. Graf, S. Goetze, E. Fleck, W. A. Hsueh, and R. E. Law. Central role of the MAPK pathway in ang II-mediated DNA synthesis and migration in rat vascular smooth muscle cells. Arterioscler.Thromb.Vasc.Biol. 19: 73-82, 1999. 159. Xin, X., S. Yang, J. Kowalski, and M. E. Gerritsen. Peroxisome proliferator-activated r e ceptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J.Biol.Chem. 274: 9116-9121, 1999. 160. Yoshimoto, T., M. Naruse, H. Shizume, K. Naruse, A. Tanabe, M. Tanaka, K. Tago, K. Irie, T. Muraki, H. D e mura, and L. Zardi. Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thic k ening and hypertensive vascular hypertrophy. Atherosclerosis 145: 333-340, 1999. 161. Zachary, I. and G. Gliki. Signaling transduction mechanisms mediating biological actions of the vascular end o thelial growth factor family. Cardiovasc.Res. 49: 568-581, 2001. 162. Zempo, N., N. Koyama, R. D. Kenagy, H. J. Lea, and A. W. Clowes. Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase i n hibitor. Arterioscler.Thromb.Vasc.Biol. 16: 28-33, 1996. 163. Zhang, Y., W. J. Cliff, G. I. Schoefl, and G. Higgins. Immunohistochemical study of intimal microvessels in coronary atherosclerosis. Am.J.Pathol. 143: 164-172, 1993. 164. Ziche, M., L. Morbidelli, R. Choudhuri, H. T. Zhang, S. Donnini, H. J. Granger, and R. Bicknell. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J.Clin.Invest 99: 2625-2634, 1997.